» Articles » PMID: 36633477

Ambulatory PH-Impedance Findings Confirm That Grade B Esophagitis Provides Objective Diagnosis of Gastroesophageal Reflux Disease

Abstract

Introduction: The Lyon Consensus designates Los Angeles (LA) grade C/D esophagitis or acid exposure time (AET) >6% on impedance-pH monitoring (MII-pH) as conclusive for gastroesophageal reflux disease (GERD). We aimed to evaluate proportions with objective GERD among symptomatic patients with LA grade A, B, and C esophagitis on endoscopy.

Methods: Demographics, clinical data, endoscopy findings, and objective proton-pump inhibitor response were collected from symptomatic prospectively enrolled patients from 2 referral centers. Off-therapy MII-pH parameters included AET, number of reflux episodes, mean nocturnal baseline impedance, and postreflux swallow-induced peristaltic wave index. Objective GERD evidence was compared between LA grades.

Results: Of 155 patients (LA grade A: 74 patients, B: 61 patients, and C: 20 patients), demographics and presentation were similar across LA grades. AET >6% was seen in 1.4%, 52.5%, and 75%, respectively, in LA grades A, B, and C. Using additional MII-pH metrics, an additional 16.2% with LA grade A and 47.5% with LA grade B esophagitis had AET 4%-6% with low mean nocturnal baseline impedance and postreflux swallow-induced peristaltic wave index; there were no additional gains using the number of reflux episodes or symptom-reflux association metrics. Compared with LA grade C (100% conclusive GERD based on endoscopic findings), 100% of LA grade B esophagitis also had objective GERD but only 17.6% with LA grade A esophagitis ( P < 0.001 compared with each). Proton-pump inhibitor response was comparable between LA grades B and C (74% and 70%, respectively) but low in LA grade A (39%, P < 0.001).

Discussion: Grade B esophagitis indicates an objective diagnosis of GERD.

Citing Articles

Long-term efficacy of on-demand vonoprazan treatment for mild reflux esophagitis: success rates and predictors of treatment failure.

Hoshikawa Y, Koeda M, Rokugo T, Momma E, Kawami N, Iwakiri K Esophagus. 2024; .

PMID: 39648266 DOI: 10.1007/s10388-024-01099-z.


The Clinical Spectrum of Gastroesophageal Reflux Disease: Facts and Fictions.

Marabotto E, Pasta A, Calabrese F, Ribolsi M, Mari A, Savarino V Visc Med. 2024; 40(5):242-249.

PMID: 39398395 PMC: 11466451. DOI: 10.1159/000536583.


pHoenix score: development and validation of a novel approach to decrease the number of inconclusive GERD diagnoses.

Latorre-Rodriguez A, Mittal S, Simmonds H, Kim P, Bremner R Surg Endosc. 2024; 38(11):6880-6893.

PMID: 39192040 PMC: 11525326. DOI: 10.1007/s00464-024-11105-1.


The real occurrence of gastroesophageal reflux disease after sleeve gastrectomy - a prospective pH-monitoring study.

Dowgiallo-Gornowicz N, Lech P Wideochir Inne Tech Maloinwazyjne. 2024; 19(2):205-210.

PMID: 38973794 PMC: 11223549. DOI: 10.5114/wiitm.2024.138521.


Prediction, prevention and management of gastroesophageal reflux after per-oral endoscopic myotomy: An update.

Nabi Z, Inavolu P, Duvvuru N World J Gastroenterol. 2024; 30(9):1096-1107.

PMID: 38577183 PMC: 10989487. DOI: 10.3748/wjg.v30.i9.1096.